These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2959202)

  • 41. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
    Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
    Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion.
    Lissoni P; Vigano P; Vaghi M; Frontini L; Giuberti C; Manganini V; Casu M; Brivio F; Niespolo R; Strada G
    Anticancer Res; 2005; 25(5):3597-9. PubMed ID: 16101186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endocrine therapy in cancer.
    Stoll BA
    Practitioner; 1979 Feb; 222(1328):211-7. PubMed ID: 86186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hormone receptors and Japanese breast cancer.
    Matsumoto K; Kitamura Y; Sugano H
    Acta Pathol Jpn; 1982; 32 Suppl 1():145-54. PubMed ID: 6764994
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action].
    Okada H
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):924-8. PubMed ID: 2968780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct antiproliferative effect of triptorelin on human breast cancer cells.
    Marini L; Iacopino F; Schinzari G; Robustelli della Cuna FS; Mantovani G; Sica G
    Anticancer Res; 1994; 14(5A):1881-5. PubMed ID: 7847821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA; Oza BP; Colomer R; Lupu R
    Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Hormone therapy of neoplasms].
    Abe K
    Nihon Naika Gakkai Zasshi; 1991 Mar; 80(3):373-6. PubMed ID: 1649883
    [No Abstract]   [Full Text] [Related]  

  • 53. [Antiestrogen therapy of patients with uterine cancer].
    Sugimura M; Terao T
    Nihon Rinsho; 1994 Mar; 52(3):804-8. PubMed ID: 8164386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fundamental research leading to improved endocrine therapy for breast cancer.
    Miller WR
    J Steroid Biochem; 1987; 27(1-3):477-85. PubMed ID: 3320538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Strategy of drug development for hormone-dependent tumor].
    Kudoh M
    Gan To Kagaku Ryoho; 1996 May; 23(6):668-72. PubMed ID: 8645015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
    Bonte J; Janssens JP; Ide P
    Eur J Gynaecol Oncol; 1986; 7(1):45-50. PubMed ID: 2938955
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endocrine factors in common epithelial ovarian cancer.
    Rao BR; Slotman BJ
    Endocr Rev; 1991 Feb; 12(1):14-26. PubMed ID: 1851084
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The endometrial adenocarcinoma as a model for hormone-dependency and hormone-responsiveness of gynaecological cancers.
    Bonte J
    Eur J Obstet Gynecol Reprod Biol; 1984 Dec; 18(5-6):335-41. PubMed ID: 6526120
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Adjuvant hormone therapy of primary breast cancer. Review of the literature].
    Focan C
    Rev Med Liege; 1991 May; 46(5):270-8. PubMed ID: 1830160
    [No Abstract]   [Full Text] [Related]  

  • 60. Steroid hormone receptors in cancer development: a target for cancer therapeutics.
    Ahmad N; Kumar R
    Cancer Lett; 2011 Jan; 300(1):1-9. PubMed ID: 20926181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.